These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 22998913)

  • 1. Natural history of biochemical recurrence after radical prostatectomy with adjuvant radiation therapy.
    Boorjian SA; Tollefson MK; Thompson RH; Rangel LJ; Bergstralh EJ; Karnes RJ
    J Urol; 2012 Nov; 188(5):1761-6. PubMed ID: 22998913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
    Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
    Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era.
    Boorjian SA; Thompson RH; Siddiqui S; Bagniewski S; Bergstralh EJ; Karnes RJ; Frank I; Blute ML
    J Urol; 2007 Sep; 178(3 Pt 1):864-70; discussion 870-1. PubMed ID: 17631342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer.
    Han M; Partin AW; Zahurak M; Piantadosi S; Epstein JI; Walsh PC
    J Urol; 2003 Feb; 169(2):517-23. PubMed ID: 12544300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
    Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
    BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detectable prostate specific antigen between 60 and 120 days following radical prostatectomy for prostate cancer: natural history and prognostic significance.
    Sengupta S; Christensen CM; Zincke H; Slezak JM; Leibovich BC; Bergstralh EJ; Myers RP; Blute ML
    J Urol; 2006 Aug; 176(2):559-63. PubMed ID: 16813889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patterns and predictors of early biochemical recurrence after radical prostatectomy and adjuvant radiation therapy in men with pT3N0 prostate cancer: implications for multimodal therapies.
    Briganti A; Joniau S; Gandaglia G; Cozzarini C; Sun M; Tombal B; Haustermans K; Hinkelbein W; Shariat SF; Karakiewicz PI; Montorsi F; Van Poppel H; Wiegel T
    Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):960-7. PubMed ID: 24351411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years.
    Amling CL; Blute ML; Bergstralh EJ; Seay TM; Slezak J; Zincke H
    J Urol; 2000 Jul; 164(1):101-5. PubMed ID: 10840432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disease progression and survival in patients with prostate carcinoma and positive lymph nodes after radical retropubic prostatectomy.
    Kroepfl D; Loewen H; Roggenbuck U; Musch M; Klevecka V
    BJU Int; 2006 May; 97(5):985-91. PubMed ID: 16643480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of factors predicting response to adjuvant radiation therapy in patients with positive margins after radical prostatectomy.
    Kamat AM; Babaian K; Cheung MR; Naya Y; Huang SH; Kuban D; Babaian RJ
    J Urol; 2003 Nov; 170(5):1860-3. PubMed ID: 14532793
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term outcome following radical prostatectomy in men with clinical stage T3 prostate cancer.
    Carver BS; Bianco FJ; Scardino PT; Eastham JA
    J Urol; 2006 Aug; 176(2):564-8. PubMed ID: 16813890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Salvage radiotherapy for isolated prostate specific antigen increase after radical prostatectomy: evaluation of prognostic factors and creation of a prognostic scoring system.
    Buskirk SJ; Pisansky TM; Schild SE; Macdonald OK; Wehle MJ; Kozelsky TF; Collie AC; Ferrigni RG; Myers RP; Prussak KA; Heckman MG; Crook JE; Parker AS; Igel TC
    J Urol; 2006 Sep; 176(3):985-90. PubMed ID: 16890677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radical prostatectomy for pathological Gleason 8 or greater prostate cancer: influence of concomitant pathological variables.
    Lau WK; Bergstralh EJ; Blute ML; Slezak JM; Zincke H
    J Urol; 2002 Jan; 167(1):117-22. PubMed ID: 11743287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increasing prostate specific antigen following radical prostatectomy and adjuvant hormonal therapy: doubling time predicts survival.
    Sengupta S; Blute ML; Bagniewski SM; Myers RP; Bergstralh EJ; Leibovich BC; Zincke H
    J Urol; 2006 May; 175(5):1684-90; discussion 1690. PubMed ID: 16600730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk stratification of patients with extraprostatic extension and negative lymph nodes at radical prostatectomy: identifying optimal candidates for adjuvant therapy.
    Eisenberg MS; Karnes RJ; Kaushik D; Rangel L; Bergstralh EJ; Boorjian SA
    J Urol; 2013 Nov; 190(5):1735-41. PubMed ID: 23727312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Time to prostate specific antigen recurrence after radical prostatectomy and risk of prostate cancer specific mortality.
    Freedland SJ; Humphreys EB; Mangold LA; Eisenberger M; Partin AW
    J Urol; 2006 Oct; 176(4 Pt 1):1404-8. PubMed ID: 16952644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isolated local recurrence is rare after radical prostatectomy in men with Gleason 7 prostate cancer and positive surgical margins: therapeutic implications.
    Han M; Pound CR; Potter SR; Partin AW; Epstein JI; Walsh PC
    J Urol; 2001 Mar; 165(3):864-6. PubMed ID: 11176487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate-specific antigen control with low-dose adjuvant radiotherapy for high-risk prostate cancer.
    Macdonald OK; Lee RJ; Snow G; Lee CM; Tward JD; Middleton AW; Middleton GW; Sause WT
    Urology; 2007 Feb; 69(2):295-9. PubMed ID: 17320667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High Gleason grade carcinoma at a positive surgical margin predicts biochemical failure after radical prostatectomy and may guide adjuvant radiotherapy.
    Savdie R; Horvath LG; Benito RP; Rasiah KK; Haynes AM; Chatfield M; Stricker PD; Turner JJ; Delprado W; Henshall SM; Sutherland RL; Kench JG
    BJU Int; 2012 Jun; 109(12):1794-800. PubMed ID: 21992536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Risk factors for biochemical recurrence after radical prostatectomy in patients with clinically localized prostate cancer. Implications of adjuvant treatment].
    Fagundo EV; Amo FH; López EL; Sánchez JP; Jiménez Gdel P; Chamizo JA; Cordero JM; Fernández ME; Fernández CH
    Arch Esp Urol; 2012; 65(1):158-65. PubMed ID: 22318186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.